Senzime AB (publ) (SEZI.ST)
SEK 3.93
(2.35%)
SEK 3.93
(2.35%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 8.33 Million SEK | 275.29% |
| 2022 | -4.39 Million SEK | 10.73% |
| 2021 | -4.92 Million SEK | 37.68% |
| 2020 | -7.89 Million SEK | 7.5% |
| 2019 | -8.53 Million SEK | -63.36% |
| 2018 | -5.22 Million SEK | -840.11% |
| 2017 | -556 Thousand SEK | -150.45% |
| 2016 | 1.1 Million SEK | 169.87% |
| 2015 | -1.57 Million SEK | 9.83% |
| 2014 | -1.74 Million SEK | 16.33% |
| 2013 | -2.09 Million SEK | -399.86% |
| 2012 | 697.11 Thousand SEK | -61.64% |
| 2011 | 1.81 Million SEK | 6.3% |
| 2010 | 1.7 Million SEK | 1.54% |
| 2009 | 1.68 Million SEK | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 3.3 Million SEK | 7.41% |
| 2024 Q2 | 4.89 Million SEK | 52.75% |
| 2023 Q4 | 3.07 Million SEK | 36.98% |
| 2023 FY | 7.7 Million SEK | 275.29% |
| 2023 Q1 | 955 Thousand SEK | -52.93% |
| 2023 Q2 | 1.84 Million SEK | 93.09% |
| 2023 Q3 | 2.24 Million SEK | 21.85% |
| 2022 Q3 | -4.52 Million SEK | -440.67% |
| 2022 Q4 | 2.02 Million SEK | 144.89% |
| 2022 FY | -4.39 Million SEK | 10.73% |
| 2022 Q2 | -836 Thousand SEK | 21.72% |
| 2022 Q1 | -1.06 Million SEK | 1.48% |
| 2021 Q3 | -1.74 Million SEK | -5732.26% |
| 2021 Q1 | -2.12 Million SEK | -17.62% |
| 2021 FY | -4.92 Million SEK | 37.68% |
| 2021 Q2 | 31 Thousand SEK | 101.46% |
| 2021 Q4 | -1.08 Million SEK | 37.92% |
| 2020 Q3 | -2.03 Million SEK | 24.5% |
| 2020 Q1 | -1.92 Million SEK | -116.42% |
| 2020 FY | -7.89 Million SEK | 7.5% |
| 2020 Q4 | -1.8 Million SEK | 11.26% |
| 2020 Q2 | -2.69 Million SEK | -40.02% |
| 2019 Q3 | -2.02 Million SEK | 24.44% |
| 2019 FY | -8.53 Million SEK | -63.36% |
| 2019 Q2 | -2.68 Million SEK | 9.45% |
| 2019 Q1 | -2.96 Million SEK | -81.17% |
| 2019 Q4 | -889 Thousand SEK | 56.16% |
| 2018 Q4 | -1.63 Million SEK | 33.33% |
| 2018 FY | -5.22 Million SEK | -840.11% |
| 2018 Q2 | -809 Thousand SEK | -147.4% |
| 2018 Q1 | -327 Thousand SEK | -12.76% |
| 2018 Q3 | -2.45 Million SEK | -203.34% |
| 2017 FY | -556 Thousand SEK | -150.45% |
| 2017 Q4 | -290 Thousand SEK | -130.16% |
| 2017 Q3 | -126 Thousand SEK | -236.96% |
| 2017 Q2 | 92 Thousand SEK | 173.6% |
| 2017 Q1 | -125 Thousand SEK | -428.95% |
| 2016 Q4 | 38 Thousand SEK | -95.15% |
| 2016 FY | 1.1 Million SEK | 169.87% |
| 2016 Q3 | 783 Thousand SEK | 102.33% |
| 2016 Q2 | 387 Thousand SEK | 464.38% |
| 2016 Q1 | -106.2 Thousand SEK | -48.32% |
| 2015 Q3 | -486.98 Thousand SEK | 8.68% |
| 2015 Q4 | -71.6 Thousand SEK | 85.3% |
| 2015 Q1 | -485.3 Thousand SEK | -207.88% |
| 2015 FY | -1.57 Million SEK | 9.83% |
| 2015 Q2 | -533.24 Thousand SEK | -9.88% |
| 2014 Q1 | -384.13 Thousand SEK | -4.02% |
| 2014 FY | -1.74 Million SEK | 16.33% |
| 2014 Q2 | -637.42 Thousand SEK | -65.94% |
| 2014 Q3 | -569.93 Thousand SEK | 10.59% |
| 2014 Q4 | -157.62 Thousand SEK | 72.34% |
| 2013 FY | -2.09 Million SEK | -399.86% |
| 2013 Q3 | -401.6 Thousand SEK | 40.57% |
| 2013 Q1 | -675.79 Thousand SEK | -27.87% |
| 2013 Q4 | -369.29 Thousand SEK | 8.04% |
| 2013 Q2 | -675.79 Thousand SEK | 0.0% |
| 2012 FY | 697.11 Thousand SEK | -61.64% |
| 2012 Q4 | -528.48 Thousand SEK | 0.0% |
| 2011 FY | 1.81 Million SEK | 6.3% |
| 2010 FY | 1.7 Million SEK | 1.54% |
| 2009 FY | 1.68 Million SEK | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Acarix AB (publ) | 5.29 Million SEK | -57.429% |
| ADDvise Group AB (publ) | 300.6 Million SEK | 97.226% |
| ADDvise Group AB (publ) | 300.6 Million SEK | 97.226% |
| Arcoma AB | 11.07 Million SEK | 24.677% |
| Bactiguard Holding AB (publ) | 139.98 Million SEK | 94.043% |
| BICO Group AB (publ) | 1.83 Billion SEK | 99.544% |
| Boule Diagnostics AB (publ) | 249.71 Million SEK | 96.661% |
| CellaVision AB (publ) | 463.04 Million SEK | 98.199% |
| Clinical Laserthermia Systems AB (publ) | 2.99 Million SEK | -178.245% |
| Chordate Medical Holding AB (publ) | -28.41 Million SEK | 129.348% |
| C-Rad AB (publ) | 66.01 Million SEK | 87.368% |
| Duearity AB (publ) | -4.17 Million SEK | 299.593% |
| Dignitana AB (publ) | 58.97 Million SEK | 85.859% |
| Episurf Medical AB (publ) | -41.8 Million SEK | 119.95% |
| Getinge AB (publ) | 13.43 Billion SEK | 99.938% |
| Scandinavian Real Heart AB (Publ) | -50.21 Million SEK | 116.606% |
| Iconovo AB (publ) | 17.57 Million SEK | 52.559% |
| Integrum AB (publ) | 690.56 Thousand SEK | -1107.567% |
| Luxbright AB (publ) | -2.79 Million SEK | 398.154% |
| Mentice AB (publ) | 236.38 Million SEK | 96.472% |
| OssDsign AB (publ) | 83.64 Million SEK | 90.03% |
| Paxman AB (publ) | 12.61 Million SEK | 33.912% |
| Promimic AB (publ) | 38.51 Million SEK | 78.349% |
| Qlife Holding AB (publ) | -50.75 Million SEK | 116.431% |
| SciBase Holding AB (publ) | 16.03 Million SEK | 48.001% |
| ScandiDos AB (publ) | 47.55 Million SEK | 82.465% |
| Sectra AB (publ) | 557.55 Million SEK | 98.504% |
| Sedana Medical AB (publ) | 108.98 Million SEK | 92.348% |
| SpectraCure AB (publ) | -9.22 Million SEK | 190.415% |
| Stille AB | 132.17 Million SEK | 93.691% |
| Vitrolife AB (publ) | 1.97 Billion SEK | 99.578% |
| Xvivo Perfusion AB (publ) | 416.91 Million SEK | 98.0% |